Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Viatris (VTRS) PT Lowered to $19 at BMO Capital
March 1, 2022 7:16 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Viatris (NASDAQ: VTRS) to $19.00 (from $23.00) while maintaining an Outperform rating.
The analyst commented, "4Q was in-line, but 2022 guidance was light (though FX is factor, guidance seems conservative). Bigger focus taking stock down was Biocon... More
Viatris (VTRS) PT Lowered to $10 at Cowen
February 28, 2022 12:16 PM ESTCowen analyst Ken Cacciatore lowered the price target on Viatris (NASDAQ: VTRS) to $10.00 (from $15.00) while maintaining a Market Perform rating following weak Q4 results and guidance, and plans to divest some franchises.
The analyst commented, "Following another weak result and 2022 guidance that... More
